the Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor Over Monotherapy on Urinary Protein in Patients With Type 2 Diabetes
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 2
- 主要终点
- urinary protein changes
研究概览
简要总结
The purpose of this study is to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.
详细描述
This project is a single-center retrospective cohort study to obtain the biochemical index levels of urinary albumin creatinine ratio, urinary protein creatinine ratio, blood renal function, blood lipids, and blood glucose at the immediate, 3rd, 6th, and 12th month of cohort inclusion in each group of patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years
- •Clinical diagnosis of type 2 diabetes mellitus
- •Immediate urine albumin creatinine ratio greater than 30mg/g
- •Signed informed consent and available for follow-up
排除标准
- •severe renal insufficiency, i.e. eGFR ≤ 30ml/min/1.75m2
- •clinical diagnosis of various acute and chronic urinary tract infections
- •combined with various serious infectious diseases
- •combined with acute complications of diabetes mellitus
- •end-stage malignancy
- •pregnancy and lactation
结局指标
主要结局
urinary protein changes
时间窗: 2023.03-2024.03
to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.
次要结局
未报告次要终点
